- Home
- IKT vs FENC Comparison
IKT vs FENC Comparison
Compare IKT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IKT | FENC |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 230.8M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IKT | FENC |
|---|---|---|
| Price | $2.00 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 933.5K | 126.7K |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $5.65 |
| 52 Week High | $2.27 | $9.92 |
Technical Indicators
Market Signals| Indicator | IKT | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 62.27 | 58.77 |
| Support Level | $1.43 | $5.65 |
| Resistance Level | $2.10 | $8.09 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 100.00 | 92.48 |
Price Performance
Historical ComparisonAbout IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.